ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Cannot have received: B7-H3 targeted therapy

Previous or current treatment with B7-H3 targeted therapy

Cannot have received: antibody-drug conjugate

Exception: ADCs with topoisomerase I inhibitors as the payload

ADCs with topoisomerase I inhibitors as the payload

Cannot have received: cytotoxic chemotherapy

Any cytotoxic chemotherapy, investigational agents and small molecule targeted therapy within 14 days prior to the first scheduled dose of HS-20093

Cannot have received: small molecule targeted therapy

Any cytotoxic chemotherapy, investigational agents and small molecule targeted therapy within 14 days prior to the first scheduled dose of HS-20093

Cannot have received: macromolecule anti-tumor therapy

Prior treatment with macromolecule anti-tumor therapy or other anticancer drugs within 28 days prior to the first scheduled dose of HS-20093

Cannot have received: other anticancer drugs

Prior treatment with macromolecule anti-tumor therapy or other anticancer drugs within 28 days prior to the first scheduled dose of HS-20093

Cannot have received: radiation therapy

Exception: limited field for palliation within 2 weeks, >30% bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to first dose

Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093

Cannot have received: major surgery

Major surgery within 4 weeks of the first dose of HS-20093